Abstract 224P
Background
Maximal heterozygosity on the human leukocyte antigen (HLA) loci was found to be associated with improved survival among NSCLC patients treated with immune checkpoint inhibitors (ICI). Here we aimed to investigate the effect of germline HLA-I/-II zygosity on clinical outcomes among NSCLC patients treated with first-line pembrolizumab in combination with chemotherapy. We explored the correlation between different HLA-A/-B supertypes and clinical outcome among the same cohort.
Methods
We prospectively collected pre-treatment blood from patients with NSCLC treated with first-line pembrolizumab in combination with chemotherapy. DNA was extracted from white blood cells and used for high resolution HLA-I/II typing. Genomic HLA-I/II homozygosity was correlated with clinical benefit. We used Sidney et al to classify genomic HLA-A and -B into supertypes.
Results
Of 65 patients recruited, 53 complied with the inclusion criteria. Of those 76%(40/53) have PD-L1 expression of <50% of their cancer cells. Our analysis did not find any association between HLA-I/-II homozygosity and clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy. However, the absence of HLA-A01 was associated with favourable PFS (HR=2.09, 95%CI 1.03-4.27, P=0.22) and improved OS (HR=2.58, 95%CI 0.96-6.89, P=0.038). the presence of HLA-B27 was associated with improved PFS (HR=0.24, 95%CI 0.12, P=0.004) but not OS.
Conclusions
The absence of association between genomic HLA-I/-II homozygosity and clinical outcome among patients with advanced NSCLC treated with pembrolizumab in combination with chemotherapy might reflect a diminished role for HLA molecules among patients with low or no PD-L1. HLA-A01 and HLA-B27 might have a role in predicting clinical outcome among this cohort of patients. Further studies are needed to explore biomarkers for this group of patients.
Clinical trial identification
NA
Editorial acknowledgement
Nil
Legal entity responsible for the study
The authors.
Funding
Higher degree by research award scheme provided by Centre for Precision Health at ECU.
Disclosure
M. Millward: Financial Interests, Personal, Advisory Board: BeiGene Australia Pty Ltd, Bristol Myers Squibb Australia Pty Ltd, AstraZeneca Australia Pty Ltd, The Limbic, Eli Lilly Australia Pty Ltd, IQVIA Australia Pty Ltd, Amgen Australia Pty Ltd, Merck Pte Ltd, Pfizer Australia Pty Ltd, Guardant Health, Roche Products Pty Ltd; Financial Interests, Personal, Full or part-time Employment, Employee: University of Western Australia; Financial Interests, Personal, Other, Consultant: Linear Clinical Research; Financial Interests, Institutional, Local PI, Trial payments to Institution: Bristol Myers Squibb, Genentech/Roche, BeiGene, Eli Lilly, Albion Laboratories, Akeso Biopharma, AbbVie, Five Prime Therapeutics, Dizal Pharma, Maxinovel, Amgen, Atridia, INXMED, Alpine Immune Sciences, Turning Point Therapeutics, IMPACT Therapeutics, Kinnate Biopharma, Rely Therapeutics, GenFleet Therapeutics, Vivace Therapeutics, Eucure Biopahrma, InventisBio, Cullinan Oncology, Tyra Biosciences, Axelia Oncology; Non-Financial Interests, Other, Scientific Advisory Committee member: Thoracic Oncology Group Australasia. E.S. Gray: Financial Interests, Personal, Invited Speaker, Invited to present at an MSD event in Melbourne, Australia: MSD Discovery Research Symposium, 28-29th October 2019, Melbourne, Victoria. “Liquid Biopsy for Predicting and Monitoring Response to Immune Checkpoint Blockade in Metastatic Melanoma Patients”: MSD; Financial Interests, Personal, Invited Speaker, Invited to present on a industry sponsored session at ESMO 2022European Society of Medical Oncology, 9-13th September 2022, Paris, France. “Circulating tumour DNA in patients with advanced ovarian cancer receiving neoadjuvant chemo-immunotherapy”: Thermo Fisher Scientific; Financial Interests, Institutional, Research Grant, Grant recipient for the following project:TCR repertoire in combination with HLA and TMB as predictor of response to immune checkpoint blockade in melanoma and lung cancer. Thermo Fisher Scientific Oncomine Clinical Research Grant. 2021. $200,000: Thermo Fisher Scientific. All other authors have declared no conflicts of interest.
Resources from the same session
165P - Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): A sub analysis of PHERGain trial
Presenter: Maria Gion Cortes
Session: Poster session 01
166P - Metabolomic prediction of breast cancer treatment toxicities
Presenter: Max Piffoux
Session: Poster session 01
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Presenter: Tan Yujing
Session: Poster session 01
168P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: SHRUTI KAHOL
Session: Poster session 01
169P - Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Presenter: Ningning Zhang
Session: Poster session 01
170P - Clinical significance and functional role of GPR56 (ADGRG1) in breast cancer
Presenter: Haizhu Chen
Session: Poster session 01
172P - T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Presenter: Nicha Zungsontiporn
Session: Poster session 01
173P - Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Presenter: Jayant Khandare
Session: Poster session 01
174P - Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Presenter: Maria Pouyiourou
Session: Poster session 01